Mark A. Agius
Affiliations: | Neuroscience | University of California, Davis, Davis, CA |
Area:
Neuroscience Biology, ImmunologyGoogle:
"Mark Agius"Mean distance: 106866
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fox RJ, Coffey CS, Cudkowicz ME, et al. (2016) Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemporary Clinical Trials |
| Hunter SF, Agius M, Miller DM, et al. (2016) Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial. Journal of the Neurological Sciences. 365: 190-8 |
| Hughes B, Cascione M, Freedman MS, et al. (2014) First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 3: 620-8 |
| Calabresi PA, Radue EW, Goodin D, et al. (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Neurology. 13: 545-56 |
| Agius M, Meng X, Chin P, et al. (2014) Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom. Cns Neuroscience & Therapeutics. 20: 446-51 |
| Berkovich R, Agius MA. (2014) Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis. Therapeutic Advances in Neurological Disorders. 7: 83-96 |
| Morell SW, Trinh VB, Gudipati E, et al. (2014) Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor. Molecular Immunology. 58: 116-31 |
| Richman DP, Nishi K, Ferns MJ, et al. (2012) Animal models of antimuscle-specific kinase myasthenia. Annals of the New York Academy of Sciences. 1274: 140-7 |
| Richman DP, Nishi K, Morell SW, et al. (2012) Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Archives of Neurology. 69: 453-60 |
| Apperson ML, Agius MA. (2011) Clinical and neuroimaging assessments for research studies (including drug trials) in multiple sclerosis. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit10.4 |